Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsA. D'Arienzo, Filippo Montemurro, Grazia Arpino et al.|EClinicalMedicine|2023Cited by 90
Insight on the Role of Leptin: A Bridge from Obesity to Breast CancerRoberto Buonaiuto, Carmine De Angelis, Fabiana Napolitano et al.|Biomolecules|2022Cited by 23
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Fabio Puglisi, Luisa Carbognin et al.|Cancer Treatment Reviews|2022Cited by 20
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approachesSara Parola, C. De Angelis, Vincenzo Di Lauro et al.|Annals of Oncology|2022Cited by 1